Biotech News

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals (APLS)Apellis Pharmaceuticals2026-01-12 12:00 ESTCommercial

Full-year 2025 preliminary 1 U.S. net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026 Strong EMPAVELI ® (pegcetacoplan) launch in C3G and primary IC-MPGN continues,

Related news

INMBINmune Bio2026-07-20 11:00 EST

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

HCWBHCW Biologics2026-05-27 11:45 EST

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

ABEOAbeona Therapeutics2026-07-21 11:30 EST

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

CAPRCapricor Therapeutics2026-05-29 01:55 EST

Capricor Therapeutics Expands Commercial Leadership Team

ABEOAbeona Therapeutics2026-08-04 11:30 EST

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

CRNXCrinetics Pharmaceuticals2026-06-02 20:05 EST

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

INMBINmune Bio2026-08-06 20:00 EST

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

BNTXBioNTech2026-08-20 09:30 EST

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

IFRXInflarx NV2026-08-06 11:30 EST

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

View all latest news

Apellis Pharmaceuticals

Complement C3 Biology Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases. SYFOVRE SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for...

Recent company news

APLSApellis Pharmaceuticals2026-03-31 10:59 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLSApellis Pharmaceuticals2026-03-02 12:00 EST

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

APLSApellis Pharmaceuticals2026-02-24 12:05 EST

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-02-23 12:00 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

APLSApellis Pharmaceuticals2026-02-19 12:00 EST

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Stock data

Close: 41.03 USD
Market cap: 5.25B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States